An exploratory phase II clinical trial of apatinib in progressive radioiodine refractory differentiated thyroid cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e18094
Abstract: e18094Background: Anti-angiogenic TKI is the most potential effective strategy for patients (pts) with progressive radioiodine refractory differentiated thyroid cancer (RAIR-DTC). This phase II tri... read more here.
Keywords: progressive radioiodine; refractory differentiated; differentiated thyroid; thyroid cancer ... See more keywords
Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Management and Research"
DOI: 10.2147/cmar.s340967
Abstract: Abstract Patients with thyroid cancer (TC) usually have an excellent prognosis; however, 5–10% of them develop an advanced disease. The prognosis of this subgroup is still favourable if the lesions respond to radioactive iodine (RAI)… read more here.
Keywords: progressive radioiodine; rai; management; management progressive ... See more keywords